Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from BerGenBio ASA ( (BRRGF) ) is now available.
BerGenBio ASA has announced a fully underwritten rights issue to raise approximately NOK 130 million, following a proposed merger with Oncoinvent ASA. The funds will support key clinical milestones, including final Phase 1 ovarian data and Phase 2 recruitment, as well as the scale-up of Radspherin® manufacturing, providing a cash runway into 2027.
The most recent analyst rating on (BRRGF) stock is a Buy with a NOK38.00 price target. To see the full list of analyst forecasts on BerGenBio ASA stock, see the BRRGF Stock Forecast page.
More about BerGenBio ASA
BerGenBio ASA is a biotechnology company based in Norway, focusing on developing innovative therapeutics for aggressive diseases, particularly in oncology. The company is involved in clinical trials and aims to advance its pipeline of cancer treatments.
YTD Price Performance: -83.01%
Average Trading Volume: 308,039
Current Market Cap: NOK54.33M
See more insights into BRRGF stock on TipRanks’ Stock Analysis page.